CELF6: A RNA-Binding Protein and Potential Drug Target (G60677)

Target Name: CELF6

NCBI ID: G60677

CELF6

CELF6: A RNA-Binding Protein and Potential Drug Target

Introduction

CELF6 (Cytosine-Eluted Ligation-Fucoside-6) is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and immune cells. It is characterized by its ability to bind to specific RNA sequences, which is essential for its function in various cellular processes. CELF6 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Expression and Localization

CELF6 is a cytoplasmic protein that is expressed in a variety of cell types, including epithelial, endothelial, and immune cells. It is predominantly expressed in the cytoplasm of these cells and is present at levels of up to 10% of total cell protein in some cell types. CELF6 is also expressed in various cell types of the human body, including the placenta, liver, and spleen.

Function and Interaction

CELF6 is a RNA-binding protein that can interact with specific RNA sequences. This interaction is critical for the protein's function in various cellular processes. CELF6 has been shown to interact with a variety of RNA molecules, including mRNAs, tRNAs, and rRNAs. These interactions are essential for the translation of RNA into proteins and for the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

CELF6 has also been shown to play a role in the regulation of cellular signaling pathways. It has been shown to interact with various signaling molecules, including TGF-β, NF-kappa-B, and PI3K. These interactions are critical for the regulation of cellular processes that are involved in cell growth, differentiation, and survival.

Drug Targeting

CELF6 has been identified as a potential drug target due to its various functions in cellular processes. CELF6 has been shown to play a role in the regulation of cell growth, apoptosis, and inflammation, making it an attractive target for small molecules. Additionally, CELF6 has been shown to be involved in the regulation of cellular signaling pathways, making it a potential target for drugs that target signaling pathways involved in cancer and neurodegenerative disorders.

CELF6 has also been shown to be involved in the regulation of stem cell biology, which is of interest in the development of tissue engineering and regenerative medicine. CELF6 has also been shown to play a role in the regulation of stem cell proliferation and the commitment of stem cells to different cell types.

Conclusion

In conclusion, CELF6 is a RNA-binding protein that plays a critical role in various cellular processes in the human body. Its function as a RNA-binding protein makes it an attractive target for small molecules and drugs that target signaling pathways involved in cancer and neurodegenerative disorders. Additionally, CELF6 has been shown to be involved in the regulation of stem cell biology, which is of interest in the development of tissue engineering and regenerative medicine. Further research is needed to fully understand the role of CELF6 in cellular processes and its potential as a drug target.

Protein Name: CUGBP Elav-like Family Member 6

Functions: RNA-binding protein implicated in the regulation of pre-mRNA alternative splicing. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of TNNT2 in a muscle-specific splicing enhancer (MSE)-dependent manner. Promotes also exon exclusion of INSR pre-mRNA

The "CELF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets